Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution.
Fulvia PimpinelliFrancesco MarchesiGiulia PiaggioDiana GiannarelliElena PapaPaolo FalcucciMartina PontoneSimona Di MartinoValentina LaquintanaAntonia La MalfaEnea Gino Di DomenicoOrnella Di BellaGianluca FalzoneFabrizio EnsoliBranka VujovicAldo MorroneGennaro CilibertoAndrea MengarelliPublished in: Journal of hematology & oncology (2021)
BNT162b2 has demonstrated to be immunogenic at different extent among the cohorts. Response was 88% and robust in MPM patients. MM patients responded significantly less, particularly those on anti-CD38-based treatment. These latter patients should be advised to maintain masks and social distancing regardless of vaccination status, and their cohabiting family members need to be vaccinated in order to reduce the risk of contagion from the family. Additional boosters and titer monitoring could be considered. Trial registration Study was formally approved by the IRCCS Central Ethical Committee of Regione Lazio in January 2021 (Prot. N-1463/21).